Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective...

MLA

Wang, Xin, et al. “Preliminary Results of the ALTER-E009 Study: Efficacy and Safety of Anlotinib Combined with Radiotherapy in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)—A Multicenter, Multi-Cohort Retrospective..” Journal of Clinical Oncology, vol. 43, Feb. 2025, p. 361. EBSCOhost, https://doi.org/10.1200/JCO.2025.43.4_suppl.361.

APA

Wang, X., Feng, G., Fu, C., Wang, F., Wang, X., Li, J., Yang, B., Jiang, Y., Xu, W., Zhang, Y., Cheng, X., Ge, X., Xia, X., Xi, H., Zhao, X., Ma, H., Zhao, X., & Li, B. (2025). Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective.. Journal of Clinical Oncology, 43, 361. https://doi.org/10.1200/JCO.2025.43.4_suppl.361

Chicago

Wang, Xin, Guojie Feng, Chengrui Fu, Fan Wang, Xinyi Wang, Jiancheng Li, Baihua Yang, et al. 2025. “Preliminary Results of the ALTER-E009 Study: Efficacy and Safety of Anlotinib Combined with Radiotherapy in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)—A Multicenter, Multi-Cohort Retrospective..” Journal of Clinical Oncology 43 (February): 361. doi:10.1200/JCO.2025.43.4_suppl.361.